START FREE TRIAL

Agilent’s $950M Biocare Acquisition Could Unlock A Powerful Recurring Revenue Flywheel

The diagnostics and life sciences equipment industry rarely stands still. But recent developments around Agilent Technologies (NYSE:A) have drawn...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Is Eli Lilly’s Orna Acquisition About RNA Or Something MUCH BIGGER?

Eli Lilly’s move to acquire Orna Therapeutics landed quietly, framed as another pipeline add-on in a year already defined...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27,...

Ascendis Pharma Becomes M&A Target Again—European Suitors In Play?

Ascendis Pharma (NASDAQ:ASND) has suddenly become one of the hottest tickers in biotech circles after its shares surged 7.5%...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...